Indivior Announces Inclusion in the S&P SmallCap 600® Index New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 Indivior Concludes Legacy U.S. Department of Justice Matter Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance Indivior to Participate in the Stifel 2025 Healthcare Conference Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation Indivior to Participate in Upcoming Investor Events Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder